Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia, Ventilator-Associated | 8 | 2019 | 43 | 2.820 |
Why?
|
| Sepsis | 8 | 2024 | 515 | 2.270 |
Why?
|
| Respiratory Insufficiency | 3 | 2022 | 247 | 1.800 |
Why?
|
| Shock, Septic | 4 | 2024 | 155 | 1.560 |
Why?
|
| Administration, Inhalation | 2 | 2019 | 190 | 1.150 |
Why?
|
| Intensive Care Units | 8 | 2022 | 524 | 1.070 |
Why?
|
| Anti-Bacterial Agents | 11 | 2024 | 2553 | 1.040 |
Why?
|
| Microbiota | 3 | 2021 | 434 | 0.970 |
Why?
|
| Bacteremia | 2 | 2020 | 428 | 0.840 |
Why?
|
| Pneumonia, Bacterial | 3 | 2019 | 80 | 0.840 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2021 | 151 | 0.780 |
Why?
|
| Noninvasive Ventilation | 1 | 2022 | 33 | 0.740 |
Why?
|
| Syphilis | 1 | 2022 | 98 | 0.710 |
Why?
|
| Coronavirus | 1 | 2020 | 27 | 0.670 |
Why?
|
| Dysbiosis | 2 | 2020 | 139 | 0.670 |
Why?
|
| Communicable Diseases | 3 | 2021 | 159 | 0.630 |
Why?
|
| Aerosols | 1 | 2019 | 64 | 0.600 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 378 | 0.580 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 389 | 0.570 |
Why?
|
| Adenosine Monophosphate | 4 | 2022 | 42 | 0.560 |
Why?
|
| Pandemics | 4 | 2021 | 1186 | 0.550 |
Why?
|
| Critical Illness | 2 | 2022 | 617 | 0.540 |
Why?
|
| Antimicrobial Stewardship | 1 | 2019 | 84 | 0.540 |
Why?
|
| Alanine | 4 | 2022 | 158 | 0.540 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 569 | 0.540 |
Why?
|
| Respiration, Artificial | 6 | 2021 | 501 | 0.540 |
Why?
|
| Isoptera | 1 | 2017 | 6 | 0.540 |
Why?
|
| Vitreous Hemorrhage | 1 | 2017 | 10 | 0.540 |
Why?
|
| Ventriculostomy | 1 | 2017 | 44 | 0.520 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2017 | 56 | 0.520 |
Why?
|
| Antiviral Agents | 5 | 2022 | 822 | 0.510 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2017 | 70 | 0.510 |
Why?
|
| Intracranial Hypertension | 1 | 2017 | 133 | 0.470 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 232 | 0.450 |
Why?
|
| Coinfection | 1 | 2016 | 188 | 0.440 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 236 | 0.430 |
Why?
|
| Double-Blind Method | 7 | 2022 | 1653 | 0.430 |
Why?
|
| Humans | 36 | 2024 | 132083 | 0.420 |
Why?
|
| Treatment Outcome | 8 | 2022 | 13014 | 0.400 |
Why?
|
| Critical Care | 2 | 2022 | 686 | 0.360 |
Why?
|
| Poisoning | 1 | 2010 | 18 | 0.340 |
Why?
|
| Biomedical Research | 1 | 2016 | 550 | 0.320 |
Why?
|
| Bacterial Toxins | 1 | 2010 | 176 | 0.310 |
Why?
|
| Adrenal Insufficiency | 1 | 2010 | 32 | 0.310 |
Why?
|
| Cardiovascular System | 1 | 2010 | 106 | 0.310 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 810 | 0.300 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 784 | 0.290 |
Why?
|
| Antigens, Bacterial | 1 | 2010 | 324 | 0.290 |
Why?
|
| Survival Analysis | 2 | 2014 | 1569 | 0.280 |
Why?
|
| Societies | 2 | 2017 | 27 | 0.260 |
Why?
|
| Ultrasonography | 2 | 2021 | 989 | 0.220 |
Why?
|
| Azetidines | 2 | 2022 | 64 | 0.210 |
Why?
|
| Purines | 2 | 2022 | 113 | 0.210 |
Why?
|
| Kidney | 1 | 2010 | 1332 | 0.210 |
Why?
|
| Cross Infection | 2 | 2016 | 343 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2022 | 283 | 0.190 |
Why?
|
| Interferon beta-1a | 1 | 2021 | 20 | 0.180 |
Why?
|
| RNA, Viral | 2 | 2021 | 565 | 0.180 |
Why?
|
| Dexamethasone | 4 | 2022 | 274 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2022 | 330 | 0.180 |
Why?
|
| Urology | 1 | 2022 | 87 | 0.180 |
Why?
|
| Dogs | 3 | 2014 | 651 | 0.180 |
Why?
|
| New York | 1 | 2021 | 72 | 0.180 |
Why?
|
| Immunization, Passive | 1 | 2021 | 128 | 0.170 |
Why?
|
| Pharynx | 1 | 2020 | 67 | 0.170 |
Why?
|
| Saliva | 1 | 2021 | 133 | 0.170 |
Why?
|
| Nose | 1 | 2021 | 102 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 299 | 0.160 |
Why?
|
| Respiratory System | 1 | 2020 | 98 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2021 | 151 | 0.160 |
Why?
|
| Mouth | 1 | 2020 | 68 | 0.160 |
Why?
|
| Amikacin | 1 | 2019 | 26 | 0.160 |
Why?
|
| Resuscitation | 1 | 2021 | 268 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2022 | 1452 | 0.140 |
Why?
|
| Hemodynamics | 1 | 2021 | 864 | 0.130 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2018 | 107 | 0.130 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 41 | 0.130 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 33 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2017 | 136 | 0.130 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 479 | 0.130 |
Why?
|
| United States | 7 | 2024 | 11630 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2018 | 232 | 0.120 |
Why?
|
| Adult | 10 | 2024 | 31544 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 217 | 0.120 |
Why?
|
| Probiotics | 1 | 2018 | 226 | 0.110 |
Why?
|
| beta-Lactamases | 1 | 2017 | 208 | 0.110 |
Why?
|
| Pituitary-Adrenal System | 1 | 2014 | 43 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 2018 | 248 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2014 | 67 | 0.110 |
Why?
|
| Oxygen | 3 | 2022 | 571 | 0.110 |
Why?
|
| Research | 1 | 2016 | 265 | 0.110 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2014 | 74 | 0.110 |
Why?
|
| Dog Diseases | 1 | 2014 | 59 | 0.110 |
Why?
|
| Male | 8 | 2022 | 64904 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 186 | 0.100 |
Why?
|
| Hydrocortisone | 2 | 2014 | 226 | 0.100 |
Why?
|
| Transaminases | 1 | 2010 | 36 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2020 | 93 | 0.080 |
Why?
|
| Aldosterone | 1 | 2010 | 65 | 0.080 |
Why?
|
| Adrenal Glands | 1 | 2010 | 46 | 0.080 |
Why?
|
| Urea | 1 | 2010 | 227 | 0.080 |
Why?
|
| Vascular Resistance | 1 | 2010 | 195 | 0.080 |
Why?
|
| Propofol | 1 | 2010 | 50 | 0.080 |
Why?
|
| Conscious Sedation | 1 | 2010 | 60 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2021 | 394 | 0.080 |
Why?
|
| Middle Aged | 5 | 2022 | 28922 | 0.070 |
Why?
|
| Medicare | 2 | 2024 | 448 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2168 | 0.070 |
Why?
|
| Creatinine | 1 | 2010 | 401 | 0.070 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 137 | 0.070 |
Why?
|
| Animals | 4 | 2017 | 34951 | 0.070 |
Why?
|
| Heart Rate | 1 | 2010 | 587 | 0.070 |
Why?
|
| Point-of-Care Systems | 1 | 2010 | 193 | 0.070 |
Why?
|
| Female | 6 | 2022 | 70664 | 0.060 |
Why?
|
| Intubation, Intratracheal | 1 | 2010 | 288 | 0.060 |
Why?
|
| Aged | 5 | 2024 | 21404 | 0.060 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 89 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2016 | 149 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2010 | 1396 | 0.060 |
Why?
|
| Reimbursement, Incentive | 1 | 2024 | 48 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 6 | 0.050 |
Why?
|
| Volunteers | 1 | 2022 | 25 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 84 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2024 | 198 | 0.050 |
Why?
|
| Risk Factors | 1 | 2017 | 10899 | 0.050 |
Why?
|
| Singapore | 1 | 2021 | 16 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 52 | 0.050 |
Why?
|
| Japan | 1 | 2021 | 154 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 185 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 372 | 0.040 |
Why?
|
| Ribonucleases | 1 | 2021 | 45 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2021 | 77 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 27 | 0.040 |
Why?
|
| Biological Transport | 1 | 2021 | 349 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 159 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 463 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4694 | 0.040 |
Why?
|
| Ethanol | 1 | 2021 | 168 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 762 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 227 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 437 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 827 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 1124 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1246 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1176 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1078 | 0.030 |
Why?
|
| Mineralocorticoids | 1 | 2014 | 6 | 0.030 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2014 | 18 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 3020 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 659 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3377 | 0.020 |
Why?
|
| Prognosis | 1 | 2023 | 5006 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1892 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6445 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1306 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 9935 | 0.020 |
Why?
|
| Adolescent | 1 | 2022 | 20532 | 0.010 |
Why?
|